4.7 Article

Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 1, Pages 234-256

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01349

Keywords

-

Funding

  1. Global Challenges Research Fund [GCRF 105123-11]

Ask authors/readers for more resources

In this study, pyrazoline analogues were designed and synthesized to mimic the structure of Mycobactin. Compounds 44 and 49 were identified as potential mycobactin biosynthesis inhibitors against mycobacteria, demonstrating effective eradication of intracellular mycobacteria. These compounds also showed stronger efflux pump inhibition compared to known inhibitors. This study provides a new strategy for combating antimicrobial resistance challenges.
In this study, we have designed and synthesized pyrazoline analogues that partially mimic the structure of mycobactin, to address the requirement of novel therapeutics to tackle the emerging global challenge of antimicrobial resistance (AMR). Our investigation resulted in the identification of novel lead compounds 44 and 49 as potential mycobactin biosynthesis inhibitors against mycobacteria. Moreover, candidates efficiently eradicated intracellularly surviving mycobacteria. Thermofluorimetric analysis and molecular dynamics simulations suggested that compounds 44 and 49 bind to salicyl-AMP ligase (MbtA), a key enzyme in the mycobactin biosynthetic pathway. To the best of our knowledge, these are the first rationally designed mycobactin inhibitors to demonstrate an excellent in vivo pharmacokinetic profile. In addition, these compounds also exhibited more potent whole-cell efflux pump inhibition than known efflux pump inhibitors verapamil and chlorpromazine. Results from this study pave the way for the development of 3-(2-hydroxyphenyl)-5-(aryl)-pyrazolines as a new weapon against superbug-associated AMR challenges.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available